Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021).

Article  PubMed  Google Scholar 

Del Bene, G. & Sternberg, C. N. Systemic chemotherapy in muscle invasive and metastatic bladder cancer: present and future. Urologia 84, 130–141 (2017).

Article  PubMed  Google Scholar 

Mari, A. et al. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. World J. Urol. 36, 157–170 (2018).

Article  PubMed  Google Scholar 

Galsky, M. D. et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J. Clin. Oncol. 29, 2432–2438 (2011).

Article  PubMed  Google Scholar 

De Santis, M. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC Study 30986. J. Clin. Oncol. 30, 191 (2012).

Article  PubMed  Google Scholar 

Suzman, D. L. et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncologist 24, 563–569 (2019).

Article  CAS  PubMed  Google Scholar 

Fradet, Y. et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann. Oncol. 30, 970–976 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Angelo, A. et al. An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next. Cancer Chemother. Pharmacol. 90, 191–205 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Marandino, L. et al. Erdafitinib for the treatment of urothelial cancer. Expert Rev. Anticancer Ther. 19, 835–846 (2019).

Article  CAS  PubMed  Google Scholar 

Maiorano, B. A., Catalano, M., Maiello, E., Roviello, G. Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually? Front. Oncol. 13, 1254906 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Von der Maase, H. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 18, 3068–3077 (2000).

Article  PubMed  Google Scholar 

Loehrer, P. J. et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10, 1066–1073 (1992).

Article  PubMed  Google Scholar 

Von Der Maase, H. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602–4608 (2005).

Article  PubMed  Google Scholar 

Sternberg, C. N. et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer 42, 50–54 (2006).

Article  CAS  PubMed  Google Scholar 

Bamias, A. et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann. Oncol. 24, 1011–1017 (2013).

Article  CAS  PubMed  Google Scholar 

Galsky, M. D. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395, 1547–1557 (2020).

Article  CAS  PubMed  Google Scholar 

Powles, T. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 931–945 (2021).

Article  CAS  PubMed  Google Scholar 

Bamias, A. et al. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. Lancet Oncol. 25, 46–61 (2024).

Article  CAS  PubMed  Google Scholar 

Powles, T. et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 21, 1574–1588 (2020).

Article  CAS  PubMed  Google Scholar 

van Heijden, M. S. et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. N. Engl. J. Med. 389, 1778–1789 (2023).

Google Scholar 

Powles, T. B. et al. LBA6 EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann. Oncol. 34, S1340 (2023).

Article  Google Scholar 

O’Donnell, P. H. et al. Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K. J. Clin. Oncol. 41, 499–499 (2023).

Article  Google Scholar 

Galsky, M. D. et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann. Oncol. 23, 406–410 (2012).

Article  CAS  PubMed  Google Scholar 

Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67–76 (2017).

Article  CAS  PubMed  Google Scholar 

Balar, A. V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483–1492 (2017).

Article  CAS  PubMed  Google Scholar 

Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ozyilkan, O. et al. Outcomes by complete response to first-line pembrolizumab or platinum-based chemotherapy in advanced urothelial carcinoma (UC) in KEYNOTE-361. J. Clin. Oncol. 41, 4513–4513 (2023).

Article  Google Scholar 

Bamias, A. et al. Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study. J. Clin. Oncol. 41, LBA441–LBA441 (2023).

Article  Google Scholar 

US Food and Drug Administration. FDA limits the use of Tecentriq and Keytruda for some urothelial cancer patients. FDA www.fda.gov/drugs/resources-information-approved-drugs/fda-limits-use-tecentriq-and-keytruda-some-urothelial-cancer-patients (2023).

European Medicines Agency. EMA restricts use of Keytruda and Tecentriq in bladder cancer. EMA www.ema.europa.eu/en/news/ema-restricts-use-keytruda-tecentriq-bladder-cancer (2023).

Virgil, H. First-line nivolumab/ipilimumab fails to improve OS vs chemotherapy in PD-L1–low unresectable or metastatic urothelial carcinoma. Cancer Network www.cancernetwork.com/view/first-line-nivolumab-ipilimumab-fails-to-improve-os-in-vs-chemotherapy-in-pd-l1-low-unresectable-or-metastatic-urothelial-carcinoma (2023).

Iacovelli, R. et al. First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial. J. Clin. Oncol. 40, 439–439 (2022).

Article  Google Scholar 

Hoimes, C. J. et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J. Clin. Oncol. 41, 22–31 (2023).

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration. FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma. FDA www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic (2023).

Siefker-Radtke, A. O. et al. Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): final results from the phase 2 Norse study. J. Clin. Oncol. 41, 4504–4504 (2023).

Article  Google Scholar 

Loriot, Y. et al. First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): a phase 3, randomized, double-blind study. J. Clin. Oncol. 40, 432–432 (2022).

Article  Google Scholar 

Grivas, P. et al. Immune checkpoint inhibitors as switch or continuation maintenance therapy in solid tumors: rationale and current state. Target Oncol. 14, 505–525 (2019).

Article  PubMed  Google Scholar 

Szabados, B. et al. Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer. Eur. Urol. 73, 149–152 (2018).

Article  PubMed  Google Scholar 

Sonpavde, G. P. et al. Impact of the number of cycles of platinum based first line chemotherapy for advanced urothelial carcinoma. J. Urol. 200, 1207–1214 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Powles, T. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383, 1218–1230 (2020).

Article  CAS  PubMed  Google Scholar 

Powles, T. et al. ASCO GU 2023: avelumab first-line maintenance for advanced urothelial carcinoma: long-term follow-up from the JAVELIN Bladder 100 Trial in subgroups defined by 1L chemotherapy regimen and analysis of OS from start of 1L chemotherapy. UroToday